AARD

EFFECT - Aardvark Therapeutics, Inc. (0001774857) (Filer)

424B5 - Aardvark Therapeutics, Inc. (0001774857) (Filer)

S-3 - Aardvark Therapeutics, Inc. (0001774857) (Filer)

10-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ARD-201 obesity program, including POWER and STRENGTH trials, on voluntary pause pending next steps with ARD-101; further guidance on the program expected in Q2 2026 Clinical and preclinical data from ARD-101 program published in Molecular Metabolism  $110.0 million in cash, cash equivalents and short-term investments as of December 31, 2025, supports projected operations into the second quarter of 2027 SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NAS

Stifel downgraded Aardvark Therapeutics from Buy to Hold and set a new price target of $6.00

Morgan Stanley downgraded Aardvark Therapeutics from Overweight to Equal-Weight and set a new price target of $7.00

RBC Capital Mkts downgraded Aardvark Therapeutics from Outperform to Sector Perform and set a new price target of $6.00

H.C. Wainwright downgraded Aardvark Therapeutics from Buy to Neutral

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS). The decision by Aardvark to voluntarily pause the HERO (NCT06828861) and open-label extension (NCT0719703

SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that (i) on February 9, 2026, five new employees were granted inducement awards consisting of stock options to purchase an aggregate of 147,213 shares of common stock and (ii) on February 11, 2026, one new employee was granted an inducement award consisting of a stock option to purchase 5,125 shares of common stock.   Each option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Induceme

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun's role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. The appointments are effective as of February 9, 2026. "These key appointments for Derrick and Nelson come at a pivotal time for Aardvark as we progress ARD-101 through Phase 3 development for the tr

SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that it has established Ardia Therapeutics, Inc. (Ardia), a new wholly-owned U.S. subsidiary. Ardia will support development of a new dermatology pipeline focused on lead asset, DIA-615, a potential topical treatment for a variety of inflammatory skin diseases, including psoriasis. Bryan Jones, Ph.D., has been named Chief Executive Officer of Ardia and has transitioned out of his current role at Aar

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that Institutional Review Board (IRB) approval has been granted in the United States for an amended protocol to its ongoing Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome (PWS). The amended protocol, submitted to the U.S. Food and Drug Administration (FDA), lowers the minimum age of eligibility for trial participation

B. Riley Securities initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $32.00

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

Oppenheimer initiated coverage of Aardvark Therapeutics with a rating of Outperform and set a new price target of $35.00

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)